Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Akebia Therapeutics (DE:AX9)
FRANKFURT:AX9
RESEARCH TOOLSreports
Holding DE:AX9?
Track your performance easily
See the Price Targets and Ratings of:
AX9 Analyst Ratings
Moderate Buy
2 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
AX9 Stock 12 Month Forecast
Average Price Target
€5.61
▲(386.61% Upside)
| Highest Price Target€6.73 | Average Price Target€5.61 | Lowest Price Target€4.49 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
H.C. Wainwright
Reiterated
09/06/24
BTIG
Reiterated
08/08/24
Best Analysts Covering Akebia Therapeutics
Which Analyst Should I Follow If I Want to Buy DE:AX9 and Sell After:
1 Month
xxx
Success Rate
8/16 ratings generated profit
Average Return
-4.62%
reiterated a xxx
rating 21 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 50.00% of your transactions generating a profit, with an average return of -4.62% per trade.
3 Months
xxx
Success Rate
6/16 ratings generated profit
Average Return
-12.34%
reiterated a xxx
rating 21 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 37.50% of your transactions generating a profit, with an average return of -12.34% per trade.
1 Year
2 Years
xxx
Success Rate
5/16 ratings generated profit
Average Return
-27.04%
reiterated a xxx
rating 21 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 31.25% of your transactions generating a profit, with an average return of -27.04% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
AX9 Analyst Recommendation Trends
Rating
Apr 24
May 24
Jul 24
Aug 24
Sep 24
Strong Buy
10
9
4
4
4
Buy
0
0
0
0
0
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
10
9
4
4
4
Each month's total comprises the sum of three months' worth of ratings.
AX9 Financial Forecast
AX9 Stock Forecast FAQ
What is DE:AX9’s average 12-month price target, according to analysts?
Based on analyst ratings, Akebia Therapeutics’s 12-month average price target is €5.61.
What is DE:AX9’s upside potential, based on the analysts’ average price target?
Akebia Therapeutics has 386.61% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Akebia Therapeutics a Buy, Sell or Hold?
Akebia Therapeutics has a consensus rating of Moderate Buy, which is based on 2 buy ratings, 0 hold ratings and 0 sell ratings.
What is Akebia Therapeutics’s share price target?
The average share price target for Akebia Therapeutics is €5.61. This is based on 2 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €6.73 ,and the lowest forecast is €4.49. The average share price target represents 386.61% Increase from the current price of €1.153.
The highest analyst share price target is €6.73 ,and the lowest forecast is €4.49. The average share price target represents 386.61% Increase from the current price of €1.153.
What do analysts say about Akebia Therapeutics?
Akebia Therapeutics’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 2 Wall Streets Analysts.
How can I buy shares of Akebia Therapeutics?
To buy shares of DE:AX9, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.